Novartis to acquire neuroscience company Cadent Therapeutics in $770m worth deal
Novartis acquisition of Cadent Therapeutics : Swiss pharma giant Novartis has agreed to acquire a US neuroscience company Cadent Therapeutics, in a deal worth up ... Read More
Biogen strikes $600m deal with Pfizer for promising schizophrenia drug
Biogen, a leading US biotechnology firm, has reached a significant agreement to acquire Pfizer's neurology drug candidate, PF-04958242, which is being developed to address cognitive ... Read More